We are live on ! Find out more
LP

LMR Partners Portfolio holdings

AUM $45.4B
1-Year Est. Return 60.68%
This Fund
S&P 500
This Quarter Est. Return
+6.26%
1 Year Est. Return
+60.68%
3 Year Est. Return
+183.94%
5 Year Est. Return
+215.13%
10 Year Est. Return
+663.15%
AUM
$6.44B
AUM Growth
+$1.57B
Cap. Flow
+$88.6M
Cap. Flow %
1.38%
Top 10 Hldgs %
67.63%
Holding
740
New
307
Increased
52
Reduced
98
Closed
260

Top Sells

Rank Stock Value
1
BABA icon
Alibaba
BABA
+$93M
2
IMMU
Immunomedics Inc
IMMU
+$61.7M
3
TAK icon
Takeda Pharmaceutical
TAK
+$43.4M
4
SONY icon
Sony
SONY
+$34.6M
5
MSFT icon
Microsoft
MSFT
+$34.1M

Sector Composition

Rank Sector Weight
1 Technology 4.35%
2 Materials 3.77%
3 Financials 3.2%
4 Consumer Discretionary 2.23%
5 Healthcare 1.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
EXPD icon
251
Expeditors International
EXPD
$22.4B
$983K 0.02%
10,340
+2,500
+32% +$228K
INGR icon
252
Ingredion
INGR
$6.4B
$945K 0.01%
+12,014
New +$926K
NLSN
253
DELISTED
Nielsen Holdings plc
NLSN
$942K 0.01%
+45,118
New +$733K
CLX icon
254
Clorox
CLX
$11.8B
$938K 0.01%
+4,647
New +$962K
TTWO icon
255
Take-Two Interactive
TTWO
$45.3B
$929K 0.01%
+4,470
New +$782K
PXD
256
DELISTED
Pioneer Natural Resource Co.
PXD
$926K 0.01%
8,130
-14,867
-65% -$1.45M
PBCT
257
DELISTED
People's United Financial Inc
PBCT
$905K 0.01%
+70,022
New +$842K
WST icon
258
West Pharmaceutical
WST
$23.3B
$903K 0.01%
+3,186
New +$894K
TVTX icon
259
Travere Therapeutics
TVTX
$5.27B
$899K 0.01%
+33,000
New +$770K
ABBV icon
260
AbbVie
ABBV
$454B
$896K 0.01%
8,363
-16,049
-66% -$1.54M
PNC icon
261
PNC Financial Services
PNC
$99.6B
$891K 0.01%
5,978
-9,353
-61% -$1.19M
AUPH icon
262
Aurinia Pharmaceuticals
AUPH
$1.96B
$880K 0.01%
63,633
FOLD
263
DELISTED
Amicus Therapeutics
FOLD
$866K 0.01%
+37,500
New +$767K
EWBC icon
264
East-West Bancorp
EWBC
$17.8B
$861K 0.01%
+16,978
New +$721K
DQ
265
Daqo New Energy
DQ
$815M
$853K 0.01%
14,865
-50,795
-77% -$2.21M
MCK icon
266
McKesson
MCK
$99.5B
$842K 0.01%
+4,843
New +$807K
VZ icon
267
Verizon
VZ
$198B
$833K 0.01%
+14,182
New +$842K
ATH
268
DELISTED
Athene Holding Ltd. Class A Common Shares
ATH
$828K 0.01%
19,200
-8,229
-30% -$326K
BALL icon
269
Ball Corp
BALL
$17.2B
$813K 0.01%
+8,726
New +$807K
CIICW
270
DELISTED
CIIG Merger Corp. Warrants
CIICW
$803K 0.01%
+97,975
New +$369K
CCX.WS
271
DELISTED
Churchill Capital Corp II Warrants, each exercisable for one share of Class A common stock at an exe
CCX.WS
$788K 0.01%
+400,000
New +$592K
REGN icon
272
Regeneron Pharmaceuticals
REGN
$69.9B
$785K 0.01%
+1,625
New +$877K
VNT icon
273
Vontier
VNT
$4.48B
$771K 0.01%
+23,095
New +$713K
TMPMU
274
DELISTED
Turmeric Acquisition Corp. Unit
TMPMU
$770K 0.01%
+75,000
New +$759K
CHRW icon
275
C.H. Robinson
CHRW
$20.6B
$763K 0.01%
8,128
+5,689
+233% +$543K

Similar funds

LMR Partners's Q4 2020 Portfolio in Review

As of Q4 2020, LMR Partners held 740 positions worth $6.44B, up 32% from $4.86B the previous quarter. Its ten largest holdings account for 68% of the portfolio.

LMR Partners's Q4 2020 filing shows 307 new, 52 increased, 98 reduced and 260 closed positions. Its largest new stake was DuPont de Nemours: 2,417,087 shares worth $216M. The largest sale was Alibaba, an estimated $93M.

By sector, the portfolio is most concentrated in Technology at 4.3% of assets, down from 6% a quarter earlier, followed by Materials and Financials.

  • LMR Partners's largest Q4 2020 buy was DuPont de Nemours: 2,417,087 shares worth $216M.
  • LMR Partners added most to Liberty Media Corporation Series C Liberty SiriusXM Common Stock in Q4 2020, an estimated $24.7M increase.
  • LMR Partners's biggest Q4 2020 reduction was Alibaba, cutting an estimated $93M.
  • LMR Partners fully exited Immunomedics Inc in Q4 2020, selling an estimated $61.7M.
  • LMR Partners's ten largest holdings make up 68% of its $6.44B portfolio in Q4 2020.
  • LMR Partners opened 307 new positions and closed 260 in Q4 2020.
  • LMR Partners's portfolio value rose 32% quarter-over-quarter to $6.44B.

Based on LMR Partners's 13F filing for Q4 2020, filed 16 Feb 2021.